ERBB2 and neoplasm: Nearly all HTM showed HER2+ tumor cells in the bone marrow (bm), but neither trastuzumab nor TMI-1 treatment was able to completely eliminate these HER2+ disseminated tumor cells (DTCs) (Table 2; Figure 4C).